Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 1.14mg equivalent to to 1 mg ropinirole - film coated tablet - 1 mg - active: ropinirole hydrochloride 1.14mg equivalent to to 1 mg ropinirole excipient: citric acid hyprolose hypromellose indigo carmine aluminium lake iron oxide yellow lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 2.28mg equivalent to to 2 mg ropinirole - film coated tablet - 2 mg - active: ropinirole hydrochloride 2.28mg equivalent to to 2 mg ropinirole excipient: citric acid hyprolose hypromellose iron oxide red lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 3.42mg equivalent to to 3 mg ropinirole - film coated tablet - 3 mg - active: ropinirole hydrochloride 3.42mg equivalent to to 3 mg ropinirole excipient: citric acid cochineal hyprolose hypromellose indigo carmine aluminium lake lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 4.56mg equivalent to to 4 mg ropinirole - film coated tablet - 4 mg - active: ropinirole hydrochloride 4.56mg equivalent to to 4 mg ropinirole excipient: citric acid ferrosoferric oxide hyprolose hypromellose iron oxide red iron oxide yellow lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

Nouvelle-Zélande - anglais - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 5.7mg equivalent to to 5 mg ropinirole - film coated tablet - 5 mg - active: ropinirole hydrochloride 5.7mg equivalent to to 5 mg ropinirole excipient: citric acid hyprolose hypromellose indigo carmine aluminium lake lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

de pharmaceuticals - ropinirole hydrochloride - oral tablet - 5mg

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

accord-uk ltd - ropinirole hydrochloride - oral tablet - 5mg

Royaume-Uni - anglais - MHRA (Medicines & Healthcare Products Regulatory Agency)

mawdsley-brooks & company ltd - ropinirole hydrochloride - oral tablet - 5mg

Singapour - anglais - HSA (Health Sciences Authority)

procter & gamble (singapore ) pte ltd - cyanocobalamin; pyridoxine hcl; thiamine disulphide - tablet, sugar coated - 200 mcg - cyanocobalamin 200 mcg; pyridoxine hcl 200 mg; thiamine disulphide 100 mg

États-Unis - anglais - NLM (National Library of Medicine)

apotheca company - levodopa (unii: 46627o600j) (levodopa - unii:46627o600j) - levodopa 30 [hp_c] in 1 ml - indications:   to be used according to standard homeopathic indications. to be used according to standard homeopathic indications.